Slide 1: Repligen Announces Agreement to Acquire Avitide, Inc.
Repligen Announces Agreement to Acquire Avitide, Inc. Tony J. Hunt, President and CEO September 16, 2021 Jon K. Snodgres, CFO Exhibit 99.2
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this presentation which are not strictly historical statements including, without limitation, express or implied statements or guidance rega
Slide 3: Strategic Acquisition Strengthens Proteins Franchise
Strengthens Core Ligand Discovery & Development Capabilities Expands in-house ligand discovery and new resin development capabilities Best-in-class ligand discovery/development lead-times Complements and Extends Work Done with Navigo GmbH Avitide focus: AAV (gene therapy), other Navigo focus: Protei
Slide 4: Technology leadership in affinity ligand discovery and development
Technology leadership in affinity ligand discovery and development Avitide and partnership with Navigo provide best-in-class screening for affinity ligand candidates across multiple modalities Avitide differentiates with speed and accuracy; ~6 weeks for ligand discovery versus standard 4-6 months St
Slide 5: Avitide Company Profile
Headquarters: Lebanon, NH Founded: 2013 Co-Founders: Kevin Isett, Ph.D. (CEO) Warren Kett, Ph.D. (CSO) Tillman Gerngross, Ph.D. (Chair) Employees: 40 Manufacturing facilities: Lebanon, NH ISO 9001:2005 certified Ligand discovery and resin development Modular operations model allows volume flexibilit
Slide 6: Ligand discovery and resin development timelines
6 weeks ligand discovery, 6 weeks resin development (target dependent) High diversity improves the overall probability of success to identify well-differentiated binders
Slide 7: Deal Summary
Deal Summary Strengthens and expands market position in affinity ligands with best-in-class platform Gives Repligen a new platform for affinity resin development, including gene therapy Complements Navigo GmbH partnership and provides affinity content to drive future growth of Proteins franchise Rap
Slide 8: Questions? Contact Investor Relations
Questions? Contact Investor Relations investors@repligen.com